1.
Rev Assoc Med Bras (1992)
; 68(6): 866-870, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35766703
2.
Rev. Assoc. Med. Bras. (1992, Impr.)
; Rev. Assoc. Med. Bras. (1992, Impr.);68(6): 866-870, June 2022. tab, graf
Artigo
em Inglês
|
LILACS-Express
| LILACS
| ID: biblio-1387149
3.
J Clin Med Res
; 12(10): 647-654, 2020 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33029271
RESUMO
Galectin-3 (Gal-3) is a biomarker of fibrosis that has been associated with atrial remodeling. Acknowledging the presence of a biomarker in patients with atrial fibrillation (AF) can allow for a better clinical treatment. The aim of this study was to assess the association of Gal-3 with atrial fibrosis in patients with AF. This is a systematic review study. From the total number of studies analyzed, 12 demonstrated a relation between atrial fibrosis and Gal-3 in patients with AF and presented statistically significant association values. We conclude that Gal-3 is associated with atrial fibrosis in patients with AF in all types, as well as after the arrhythmia treatment by ablation.